Sunitinib and Immunotherapy: — Where Combinations Fit in Kidney Cancer

A TKI like sunitinib targets specific proteins in the pathway that kidney tumours use to grow blood vessels. It interferes with a particular molecular mechanism rather than killing cells directly. Checkpoint inhibitors — the immunotherapy type used in kidney cancer — work differently: they do not target the tumour itself but remove the molecular signals that allow cancer cells to hide from your immune system. The two approaches attack the disease through separate pathways, which is the biological rationale for combining them.

The checkpoint inhibitors used in approved kidney cancer combination regimens include pembrolizumab, nivolumab and avelumab. They are paired with a TKI — axitinib, cabozantinib or lenvatinib — or, in the case of nivolumab plus ipilimumab, with a second checkpoint inhibitor rather than a TKI. Which regimen your oncologist recommends depends on your tumour subtype, risk category and individual factors. NCCN, ASCO and ESMO publish regularly updated guidance on which combinations are preferred for which patient groups.

Sunitinib was the first drug to show a clear improvement over the previous standard in advanced clear cell kidney cancer, which made it the benchmark against which new treatments had to prove themselves. When researchers began testing TKI-immunotherapy combinations, sunitinib was that benchmark. The specific TKIs chosen as combination partners were selected partly because they showed better tolerability than sunitinib in early-phase studies pairing TKIs with checkpoint inhibitors. This is a practical point about drug development rather than a statement about which TKI is inherently better.

Your oncologist will arrange imaging at regular intervals — usually a CT scan, or in some cases a PET-CT coordinated through partner imaging centres — to assess whether the tumour has responded, stayed stable or progressed. They will also look at your symptoms and blood markers. Response is assessed against established criteria, and your team will explain what they are looking for at each scan. If you are unsure what your latest results showed or what counts as a meaningful response, ask for a plain explanation at your next appointment.

Immunotherapy is given as day care at CION centres, and response-assessment imaging such as PET-CT is coordinated with partner imaging centres. CION does not provide CAR-T or cell therapy; if that is being considered for you, you would be referred to a centre that offers it. For questions about which specific regimen is recommended for your situation, speak with your treating oncologist, who will also be aware of any access or logistical factors relevant to your centre.

Sunitinib alone typically causes fatigue, hand-foot skin reaction, high blood pressure, diarrhoea and nausea. Adding a checkpoint inhibitor introduces a different category of risk: immune-related reactions, where the activated immune system can inflame the gut, liver, lungs, skin or hormone-producing glands. A combination therefore carries side effects from both drug classes, and some immune reactions need prompt treatment if they occur. Your team will go through the warning signs before you start. The specific profile also varies between combinations — axitinib, cabozantinib and lenvatinib each have their own patterns — so ask about the particular drugs you are on.